Compare Moderna, Inc. (MRNA) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Target Corporation — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Target Corporation trades at $153.77 (market cap $70.31B). The key difference: Moderna, Inc. and Target Corporation are close in size by market cap, and Target Corporation pays a 3% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Target Corporation for 137 Days on average.
| MRNA | TGT | |
|---|---|---|
Market Cap | $78.65B | $70.31B |
Volume | 37,373,437 | 4,164,999 |
Sector | Health | Consumer Staples |
52-Week High | $225.00 | $169.90 |
52-Week Low | $22.36 | $83.68 |
Typical Hold Time | 59 Days | 137 Days |
Enterprise Value | $74.80B | $83.58B |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Target Corporation (TGT) trades at $154.76, up 2.52% with strong recent earnings beats. The stock shows bearish technical signals but maintains solid fundamentals with a 26.41% ROE and 4.08% net margin. Recent price cuts on 2,000 items aim to capture holiday market share, while analyst consensus targets $167.18 with 47% buy ratings. Cash flow remains positive at $957M despite competitive retail pressures.
Target presents a mixed outlook with valuation appeal (P/E 16.05) against bearish technicals. Upside potential exists from continued earnings outperformance and dividend stability, but risks include margin pressure from price investments and weak consumer spending. The stock offers value for patient investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
